Breakthrough in Asthma and COPD Treatment
Doctors are celebrating a groundbreaking advancement in the treatment of asthma and chronic obstructive pulmonary disease (COPD)—the first major breakthrough in 50 years. A recent trial has demonstrated that a single injection of benralizumab significantly outperforms current standard care, reducing the need for further treatment by 30% and offering a safer alternative to steroid tablets.
Transformative Trial Results
The study, published in The Lancet Respiratory Medicine, highlights the potential of benralizumab, a monoclonal antibody that targets eosinophils—a type of white blood cell responsible for inflammation in the lungs. Traditionally used in low doses as a repeat treatment for severe asthma, the trial explored the impact of a higher single dose administered during a flare-up. The results were transformative: patients experienced fewer exacerbations, faster recovery, and improved quality of life.
Lead investigator Professor Mona Bafadhel of King’s College London hailed the findings as a potential “gamechanger.” She explained, “Treatment for asthma and COPD exacerbations has remained stagnant for five decades, despite these conditions contributing to 3.8 million deaths annually. Benralizumab offers a safer, more effective alternative to steroids, which carry severe side effects like an increased risk of diabetes and osteoporosis.”
How the Trial Was Conducted
The trial involved 158 patients who sought emergency care for asthma or COPD attacks. A quick blood test determined whether their condition was an “eosinophilic exacerbation,” which affects roughly 50% of asthma patients and 30% of those with COPD. Participants were divided into three groups:
- Group 1: Received the benralizumab injection and placebo tablets.
- Group 2: Received standard care with prednisolone steroids (30mg daily for five days) and a placebo injection.
- Group 3: Received both the benralizumab injection and steroids.
Results after 28 days showed superior outcomes for those treated with benralizumab, including better control of respiratory symptoms such as coughing, wheezing, and breathlessness. At 90 days, the failure rate for treatment in the benralizumab group was four times lower than in those on steroids, with fewer GP or hospital visits required.
A Safer and More Accessible Treatment
Unlike steroids, which pose long-term risks like diabetes and bone loss, benralizumab appears to be both effective and safer. Researchers suggest it could be administered not only in emergency settings but also at home or in general practice.
Dr. Sanjay Ramakrishnan, clinical senior lecturer at the University of Western Australia and first author of the study, emphasized the urgency of this innovation. “COPD is the third leading cause of death worldwide, yet treatments remain outdated. Benralizumab offers a modern, life-saving solution for patients who desperately need better options.”
A Call for More Lung Health Research
The findings have sparked renewed calls for greater investment in respiratory health research. Dr. Samantha Walker, director of research and innovation at Asthma and Lung UK, expressed both optimism and frustration: “It’s appalling that this is the first new treatment for asthma and COPD attacks in 50 years. This highlights how underfunded lung health research has been. We need to prioritize these patients’ needs and ensure they have access to the best possible care.”
With its potential to revolutionize treatment for millions of asthma and COPD patients, benralizumab stands as a beacon of hope, offering not just improved health outcomes but also a pathway to a better quality of life.
About The Author
